INTRODUCTION
Cyclosporin A is a potent immunosuppressive agent of significant clinical importance due to its w x widespread use in organ transplantation 1, 2 and w x also in the treatment of autoimmune diseases 3 . However, the therapeutic use of CsA is now seen to produce serious side effects, such as nephrotoxicity w x and drug-related hypertension 4᎐7 .
Ž . The mechanism s involved in the CsA-induced rise in systemic arterial blood pressure remain unclear. However, several pathophysiological changes have been proposed, including: a direct CsA-induced Ž increase in vascular smooth muscle contractility e.g.
. increase in calcium influx andror mobilization w x 8᎐13 ; a CsA-induced change in the production of vasoactive substances, such as thromboxane, w x endothelin or serotonin 14᎐16 or CsA-induced increase in sympathetic nerve activity. Early studies have reported increased activity of sympathetic w x nerves 17, 18 and pre-synaptic neurotransmitter w x release 12, 19 and, although the causes of the CsA-induced hypertension are undoubtedly multiw w x x factorial see refs 4, 6, 20, 21 for review , there is evidence suggesting that sympathetic hyperactivity is w x involved 17᎐19, 22᎐27 .
Ž . The sympathetic nervous system SNS can modulate cardiac output and peripheral vascular resistance, which determines arterial blood pressure. So, an abnormality in the SNS might contribute to the w development or maintenance of hypertension 28, x 29 . A number of studies on the connection between the SNS and hypertension have been based on mea-Ž . surements of plasma or tissue catecholamine CA concentrations. Although plasma CA physiological variability can be used to study the SNS's response to standardized stimulation, a reliable evaluation of basal SNS tone is more difficult to accomplish by measuring only plasma catecholamine levels. In order to overcome this problem, some authors have suggested the parallel study of platelet CA content w x 30, 31 . The platelet, due to its embryogenetic, biochemical and morphofunctional features, has been proposed as a peripheral model of the Ž . monoaminergic neuron serotonergic, in particular w x 32 . However, platelets have also been shown to selectively uptake catecholamines from the plasma from many areas of the body, and to store them for relatively long periods, thus overcoming possible regional differences. Since platelets are not capable of synthesizing CA, their content derives entirely from the catecholamines released into the bloodstream by the SNS terminals and can be considered a reliable w x and stable long-term index of SNS activity 30, 31 . In the present study, we have evaluated both catecholamine platelet and plasma levels in rats, some of which were treated with cyclosporin A. The aim was to identify a link between possible differences between groups and changes in blood pressures, also evaluated.
MATERIALS AND METHODS

Animals and diets
Ž Male Wistar rats Charles River Laboratories Inc., . Barcelona, Spain , ; 300 g, were maintained in an air conditioned room, subjected to 12 h darkrlight cycles, and given standard laboratory rat chow and free access to tap water. Animal experiments were carried out in agreement with the European Convention on Animal Care, and the whole research project in which these studies are included received the approval of the Portuguese National Foundation for Science and Technology. Three groups were Ž . formed: one receiving only orange juice control and the others receiving 5 and 30 mg kg y1 of CsA
Ž . Switzerland ᎏCsA 5 and CsA 30 , respectively, dissolved in orange juice, daily, for 7 weeks.
Ž . Blood pressure values systolic, diastolic and mean were estimated using a tail-cuff sphygmomanometer. Platelet count and mean platelet volume were measured with a 'Coulter' counter.
Measurements of catecholamines
Plasma and platelet catecholamines were meaw x sured as previously described 33 . Following intraperitoneal ketamine anaesthesia, blood was withdrawn by venipuncture from the jugular vein into an Ž
y1
. anticoagulant solution 0.1 ml ml blood contain-Ž . Ž . Ž . ing in mM citric acid 71 , sodium citrate 85 and Ž . D-glucose 111 . PRP was prepared by low-speed Ž centrifugation 160 g for 10 min, at room tempera-. ture and then separated into platelet and plateletpoor-plasma fractions. To 2 ml of each of these fractions, 100 ng ml y1 of the internal standard 3,4-Ž . dihydroxybenzylamine DHBA , 50 mg of alumina Ž . and 1 ml of Tris buffer 1 M, pH 8.6 were added. The mixture was then shaken for 10 min, allowed to Ž . stand for a few minutes to sediment alumina , and the supernatant was aspirated. The alumina was then washed three times with water and transferred to an appropriate microfilter system, where adsorbed catecholamines were finally obtained by centrifuga-Ž . tion 1000 g for 1 min after having added perchlo-Ž . ric acid 100 mM . The catecholamines were quantified by HPLC with electrochemical detection. The chromatographic system consisted of a Gilson Applied Chromatographic System with a 305 model pump and a 231 injection valve model, with a 50-l Ž loop. A Biophase ODS RP18 analytical column 250 . = 4.6, л s 5 ; Bioanalytical Systems Inc., USA was used and separation was made possible by using an isocratic solvent system consisting of an Ž acetate᎐citrate buffer sodium acetate 0. 
Statistical analysis
Data are expressed as means " SE of the mean Ž . SEM of n experiments. Groups were tested for differences by using the ANOVA and Fisher's test.
RESULTS
Blood pressures
Ž . Ž . Ž . Systolic SBP , diastolic DBP and mean MBP blood pressure measurements were performed in all the rats from the control and CsA-treated groups, Ž . before starting the administrations week 0 and after 2, 4 and 7 weeks. Significant increases in systolic, diastolic and mean blood pressures were obtained for the cyclosporin A-treated groups, after 2, 4 and 7 weeks, when compared with the control Ž .Ž . group P-0.05 Table I .
Plasma and platelet catecholamine concentrations
Ž . Plasma and platelet noradrenaline NA , Ž . Ž . adrenaline AD and dopamine DA levels were measured in the control and CsA-treated groups at week 0, 2, 4 and 7 of treatment.
Plasma NA, AD and DA values for the rats of the NAᎏ1367 " 23 pg ml , ADᎏ306 " 8 pg ml y1 . and DAᎏ368 " 14 pg ml , when compared with Ž y1 the control rats NAᎏ620 " 24 pg ml , ADᎏ256 y1 . " 6 pg ml , DAᎏnot detected and P-0.05 . In-Ž y1 . versely, plasma NA 514 " 22 pg ml and AD Ž y1 . Ž . 237 " 5 pg ml decreased in the CsA 5 group, Ž . but without statistical significance P-0.05 . The same pattern of changes was noticed after 4 and 7 weeks: plasma NA and AD progressively increased Ž . in the CsA 30 group and was maintained lower, but Ž . non-significant, in the CsA 5 group, when indicates the difference P-0.05 between the control group and each of the CsA-treated group. indicates the difference P-0.05 between the control group and each of the CsA-treated group.
. Ž . P-0.05 Fig. 4 . The values registered after 4 and 7 weeks confirmed those obtained after 2 weeks: sig-Ž . nificant increases of NA and AD in the CsA 30 -Ž . treated group and slight decreases in the CsA 5 -treated group, when compared with the control group.
Platelet count and mean platelet¨olume
Ž . Ž . Platelet count PLT and volume MPV were also measured following 0, 2 and 7 weeks of treatment. As one can see in Table III , no significant differences were obtained between the control and each of CsA-treated groups, at any stage.
DISCUSSION
In this study we have tested the effect of two indicates the difference P-0.05 between the control group and each of the CsA-treated group. cyclosporin A doses on rat plasma and platelet catecholamines content over 7 weeks. The choice of 30 and 5 mg kg y1 of CsA was based on the fact that these doses corresponds to 'peak' and 'trough' CsA concentrations achieved in human blood in clinical practice, immediately after an intake of a daily dose of CsA and when the blood concentration stabilizes, respectively. As initially hypothesized, they do have different effects on catecholamines levels. So, while for the group of rats taking 30 mg kg y1 of CsA the plasma and platelet CA content increased significantly when compared with the control group, there was a slight decrease for the group of rats treated with 5 mg kg y1 . The idea of test catecholamine levels between 2 and 7 weeks of treatment was based on the assumption that they reflect acute and chronic situations, respectively. In fact, 'peak' CsA concentration effects were already observed after 2 weeks Ž and still increased until the last measurements week . 7 , while the slight effects of 'trough' concentration were basically maintained after the first measure-Ž . Ž . ment week 2 , until the last week 7 .
Plasma and platelet catecholamines changed coherently in the two groups of CsA-treated rats. So, Ž . CsA 30 progressively increased NA, AD and DA levels in plasma as well as NA and AD in platelets, Ž . and CsA 5 slightly decreased NA and AD concentrations in the plasma and in the platelets too. As platelets lack the necessary enzymes for catecholamine synthesis, the amount of noradrenaline and adrenaline present in platelets is ultimately dependent on plasma levels. Some authors highlight this idea, suggesting that platelet CA content does not merely reflect the circulating concentrations of plasma CA, but it is rather the result of a dynamic w x balance between these two compartments 34 . Taking all this data into consideration, it seems that 'peak' and 'trough' CsA concentrations promoted synchronous increases and decreases, respectively, in plasma and platelet levels of catecholamines.
The role of the sympathetic nervous system in the CsA-induced increased blood pressure has already been studied by other investigators. Some of them emphasized the importance of sympathetic activaw x tion 17᎐19, 22᎐27 , while others did not identify any significant link between the rise in blood pressure w x and sympathetic activation 35᎐37 . Even the studies on catecholamines content revealed contradictory results, reporting increases, decreases or nonw x w x significant changes 38᎐42 . Grobecker et al. 27 reported that depletion of catecholamine stores by reserpine had decreased the CsA-induced hypertension significantly. Other studies, focusing on the y1 Ž effects of 5, 10 and 20 mg kg of CsA daily . administered to rats during 3 weeks in plasma catecholamine concentration, showed interesting conw x nections to our results. Gerkens et al. 39 obtained a decrease in the plasma NA levels for the group of rats administered with 5 mg kg y1 of CsA, when compared with the control group, as was also obtained by us. They did not test the effect of 30 mg kg y1 of CsA, but found that for 10 and 20 mg kg y1 there were no significant differences, when compared with the control group. So, to a certain extent, our results are connected to and are an extension of those obtained by them, revealing important increases in plasma and also in platelet cate-Ž . cholamines not evaluated in their study for a higher CsA concentration than those tested by them.
In our study blood pressures rose significantly in both CsA-treated groups, despite a decrease in plasma and platelet catecholamine levels in the Ž group treated with the 'trough' CsA concentration 5 y1 . mg kg . These data suggest that, despite altered CA distribution in the plasma and platelets could represent an important factor for the CsA-induced hypertension at high doses, other different contributions should be expected, at least when CsA is administered in low doses. CsA-induced increased catecholamine metabolization, namely by increased Ž . monoamineoxidase MAO activity, could explain normal and even lower plasma and platelet catecholamines levels than those of the control, despite of greater blood pressure increases, when compared with the high CsA concentration. However, this effect was not tested and, it remains as a speculation. On the other hand, as already demonstrated in other studies carried out in our laboratory, the 'trough' Ž y1 . CsA dose 5 mg kg is able to promote important changes in the platelet 5-HT and TXA content and 2 w x aggregation 43 , factors that may be also involved in the development of hypertension. However, we can Ž y1 . say that, at least 'peak' CsA 30 mg kg dose promotes important changes in the sympathetic nervous system, which results in increased plasma and platelet catecholamines content that may certainly affect platelet function and vascular smooth muscle cell response. Both adrenaline and noradrenaline, to less extent, induce platelet aggregation in¨itro, but the concentrations required to promote in¨i¨o responses are far lower than circulating plasma levels.
However, catecholamines amplify the effects of other agonists and, at higher concentrations, induce platelet response, including aggregation, secretion w x and arachidonate pathway activation 44 . On the other hand, increased circulating catecholamines content could represent increased stimulation of vascular smooth muscle ␣-adrenergic receptors. As ␣ and ␣ adrenergic receptors can mediate 1 2 vasoconstriction in most vascular beds, hyperresponsiveness of vascular smooth muscle to ␣-adrenergic receptor-mediated vasoconstriction is probably a key factor involved in the development andror maintenance of high vascular resistance, which determines hypertension. The mechanisms by which the high dose of cyclosporin A increased plasma and platelet catecholamines level cannot be addressed considering only the data presented in this paper. Anyway, increased NA, AD and DA concentrations suggest, at least, that CsA may affect their synthesis, namely by the adrenals, or their release from sympathetic nerve endings. Previous studies realized in our laboratory w x 45 demonstrated that the catecholamines level in the rat adrenals did not change significantly when Ž submitted to the same cyclosporin A dose 30 mg y1 . kg , suggesting that increased circulating catecholamines may result from increased release from the nerve endings. Therefore, this hypothesis was w x already formulated by Xue et al. 12 but still remains without an undoubtedly confirmation. However, our previous data seems to be in agreement with that since, in aorta segments obtained from rats treated with the same dose of CsA, the endogeneous catecholamines content decreased significantly when w x compared with the control ones 45, 46 . On the other hand, increased 3 H-NA release in the presence of CsA was also observed, which reinforce w x these supposition 45, 46 . Anyway, further studies are needed in order to clarify the origin and confirm the relevance of circulating catecholamines to the CsA-induced hypertension.
